Due to controversies surrounding the use of adjuvant osimertinib in patients with early-stage EGFR-mutated NSCLC, we performed a Delphi survey to explore expert opinions regarding the current treatment approach in this setting. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.